Results 41 to 50 of about 31,170 (214)

Losartan protects against osteoarthritis by repressing the TGF-β1 signaling pathway via upregulation of PPARγ

Journal of Orthopaedic Translation, 2021
Objective: Losartan and activation of the peroxisome proliferator-activated receptor-γ (PPARγ) have been previously reported to alleviate the progression of osteoarthritis (OA).
Zhenhan Deng, MD, Ph.D, Fei Chen, Ph.D, Yuwei Liu, MD, Ph.D, Jinping Wang, Ph.D, Wei Lu, MD, Ph.D, Wei Jiang, MD, Ph.D, Weimin Zhu, MD, Ph.D   +6 more
doaj   +1 more source

Review of the Molecular and Developmental Basis of Myhre Syndrome, Bench Research

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre syndrome (MS) is a connective‐tissue disorder within the acromelic dysplasia spectrum. It is characterized by congenital craniofacial, skeletal, cutaneous anomalies, respiratory, cardiovascular along with intellectual disability, deafness, and progressive fibrosis.
Camille Viaut, Valerie Cormier‐Daire
wiley   +1 more source

Ultrasound‐Guided Hip Pericapsular, Rectus Femoris Peritendinous, and Iliopsoas Bursa Injections Improve Extra‐articular Post‐arthroscopy Hip Pain

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To determine the short‐ and medium‐term efficacy of ultrasound‐guided hip pericapsular, rectus femoris peritendinous, and iliopsoas bursa injections with anesthetic and corticosteroid to treat post‐arthroscopy hip pain, and if any operative variables correlated with response likelihood.
Meghan E. Sahr, Hanley Ong, Karthik Krishnan, Shu‐Han Wang, Danyal H. Nawabi, Theodore T. Miller   +5 more
wiley   +1 more source

Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia

, 1999
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemiaBackgroundLosartan, an angiotensin II receptor antagonist, has been shown to decrease serum uric acid and to increase urinary excretion of uric acid.MethodsTo determine if ...
Carides, Alexandra D., Umans, Jason G., Simpson, Roger L., for the Losartan Uric Acid Study Group,, Thiyagarajan, Balasamy, Coe, Fredric L., Parks, Joan H., Shahinfar, Shahnaz, Nakagawa, Yasushi   +8 more
core   +1 more source

Dissociation between the circulating renin-angiotensin system and angiotensin II receptors in central losartan-induced hypertension

Brazilian Journal of Medical and Biological Research, 2002
Losartan, an AT1 angiotensin II (ANG II) receptor non-peptide antagonist, induces an increase in mean arterial pressure (MAP) when injected intracerebroventricularly (icv) into rats.
A.M. Sugawara, R.C. Vendramini, S.P. Barbosa, I.L. Brunetti, J.V. Menani, L.A. De Luca Jr.   +5 more
doaj   +1 more source

Arthroscopic Segmental Labral Reconstruction Using a Presutured Iliotibial Band Allograft Soaked in Bone Marrow Aspirate Concentrate

Arthroscopy Techniques, EarlyView.
Abstract Labral reconstruction is a surgical procedure in which a graft is used to replace irreparable acetabular labral tissue. Biologic augmentation with bone marrow aspirate concentrate harvested from the ipsilateral iliac crest is increasingly used to enhance graft incorporation and potentially improve functional outcomes, especially in patients ...
Jacob D. Kodra, Arthur Saroyan, Kevin Lord, Andrew Schab, Jeremy K. Ansah‐Twum, Jon Salandra, Renato Locks, Andrew E. Jimenez   +7 more
wiley   +1 more source

Losartan-induced hepatic injury

, 2002
Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug has demonstrated that it is safe. Losartan-induced hepatic toxicity is extremely rare.
Ozaras, Reşat, Mert, Ali, Tabak, F, Ozturk, Recep, AKTUĞLU, Yıldırım, Bıyıklı, Mithat, Senturk, Hakan, Ozbay, Gülşen   +7 more
core   +1 more source

Pharmacokinetic interaction of drugs, the metabolisable cytochrome P450 isoenzyme CYP2C9

Фармакокинетика и Фармакодинамика, 2020
The role of cytochrome P450 isoforms CYP2C9 and in the metabolism of losartan described. Losartan pharmacokinetics data in humans and laboratory animals are presented.
O. G. Gribakina, G. B. Kolyvanov, A. A. Litvin, A. O. Viglinskaya, V. P. Zherdev   +4 more
doaj  

Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications

Frontiers in Pharmacology, 2014
Introduction: There is an urgent need for health authorities across Europe to fully realise potential savings from increased use of generics to sustain their healthcare systems.
James eMoon, Brian eGodman, Brian eGodman, Max ePetzold, Samantha eAlvarez-Madrazo, Kathleen eBennett, Iain eBishop, Anna eBucsics, Ulrik eHesse, Andrew eMartin, Steven eSimoens, Corinne eZara, Rickard E Malmstrom   +12 more
doaj   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source